Literature DB >> 10223247

"Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.

A Perry1, B W Scheithauer, S L Stafford, C M Lohse, P C Wollan.   

Abstract

BACKGROUND: Due to the rarity of malignancy in meningiomas, prior studies have been limited to small series. Controversies regarding the definition of malignant meningioma have complicated matters further. Although histologic anaplasia and extracranial metastasis are established criteria, the former is difficult to define and the latter represents a clinical finding. Traditionally, brain invasion has also been accepted, although this has recently been debated. In a prior series, the authors were unable to prove that 23 meningiomas that had invaded the brain were more aggressive than atypical meningiomas.
METHODS: The authors expanded their analysis to include 116 patients diagnosed with "malignant meningioma" due to brain invasion, frank anaplasia (20 mitoses per 10 high-power fields or histology resembling carcinoma, sarcoma, or melanoma), and/or extracranial metastasis. Patients were followed until death or for a median of 3.7 years.
RESULTS: Survival time was highly variable, ranging from 10 days to 24 years. In multivariate analysis, histologic anaplasia (P=0.0035), subtotal resection (P=0.0038), 20 mitoses per 10 high-power fields (P=0.0071), and nuclear atypia (P=0.0068) were associated with poor survival. Of the 89 cases of meningioma that had invaded the brain, 23% were otherwise benign, 61% were otherwise atypical, and 17% were frankly anaplastic. Those without anaplasia behaved similarly to atypical meningiomas from the authors' prior study. In contrast, anaplastic meningiomas were usually fatal, associated with a median survival of 1.5 years.
CONCLUSIONS: Based on these findings, the authors suggest that brain invasion constitutes an additional criterion for the diagnosis of atypical meningioma (World Health Organization [WHO] Grade II), whereas frank anaplasia indicates high grade (WHO Grade III-IV) malignancy.

Entities:  

Mesh:

Year:  1999        PMID: 10223247     DOI: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  136 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

3.  Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act.

Authors:  Therese A Dolecek; Emily Van Meter Dressler; Jigisha P Thakkar; Meng Liu; Abeer Al-Qaisi; John L Villano
Journal:  Cancer       Date:  2015-04-14       Impact factor: 6.860

4.  Meningioma: a clinicopathological evaluation.

Authors:  Nasrin Samadi; Seyed Ali Ahmadi
Journal:  Malays J Med Sci       Date:  2007-01

5.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Authors:  Mark A Watson; David H Gutmann; Kelly Peterson; Michael R Chicoine; Bette K Kleinschmidt-DeMasters; Henry G Brown; Arie Perry
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

7.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

8.  Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density.

Authors:  Valeria Barresi; Enrica Vitarelli; Serenella Cerasoli
Journal:  Virchows Arch       Date:  2009-03-19       Impact factor: 4.064

9.  Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Authors:  C Leland Rogers; Arie Perry; Stephanie Pugh; Michael A Vogelbaum; David Brachman; William McMillan; Joseph Jenrette; Igor Barani; Dennis Shrieve; Andy Sloan; Joseph Bovi; Young Kwok; Stuart H Burri; Samuel T Chao; Aaron C Spalding; Mitchell S Anscher; Beatrice Bloom; Minesh Mehta
Journal:  Neuro Oncol       Date:  2015-10-22       Impact factor: 12.300

10.  Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.

Authors:  Hong-Lin Ke; Rong-Hu Ke; Shi-Ting Li; Bin Li; Hai-Tao Lu; Xiao-Qiang Wang
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.